292 related articles for article (PubMed ID: 29330109)
1. Friend or Foe: MicroRNAs in the p53 network.
Luo Z; Cui R; Tili E; Croce C
Cancer Lett; 2018 Apr; 419():96-102. PubMed ID: 29330109
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs as Key Effectors in the p53 Network.
Goeman F; Strano S; Blandino G
Int Rev Cell Mol Biol; 2017; 333():51-90. PubMed ID: 28729028
[TBL] [Abstract][Full Text] [Related]
3. p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes.
Pappas K; Xu J; Zairis S; Resnick-Silverman L; Abate F; Steinbach N; Ozturk S; Saal LH; Su T; Cheung P; Schmidt H; Aaronson S; Hibshoosh H; Manfredi J; Rabadan R; Parsons R
Mol Cancer Res; 2017 Aug; 15(8):1051-1062. PubMed ID: 28483946
[No Abstract] [Full Text] [Related]
4. Mutant p53 exerts oncogenic effects through microRNAs and their target gene networks.
Li XL; Jones MF; Subramanian M; Lal A
FEBS Lett; 2014 Aug; 588(16):2610-5. PubMed ID: 24726728
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.
Pfister NT; Prives C
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 27836911
[TBL] [Abstract][Full Text] [Related]
6. [miR-34s--a tumor suppression protein p53 highly related microRNA].
Lou WJ; Chen Q; Liu L; Qian C
Yi Chuan; 2010 May; 32(5):423-30. PubMed ID: 20466628
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex.
Garibaldi F; Falcone E; Trisciuoglio D; Colombo T; Lisek K; Walerych D; Del Sal G; Paci P; Bossi G; Piaggio G; Gurtner A
Oncogene; 2016 Jul; 35(29):3760-70. PubMed ID: 26996669
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity.
Gurtner A; Falcone E; Garibaldi F; Piaggio G
J Exp Clin Cancer Res; 2016 Mar; 35():45. PubMed ID: 26971015
[TBL] [Abstract][Full Text] [Related]
9. Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis.
McCubrey JA; Lertpiriyapong K; Fitzgerald TL; Martelli AM; Cocco L; Rakus D; Gizak A; Libra M; Cervello M; Montalto G; Yang LV; Abrams SL; Steelman LS
Adv Biol Regul; 2017 Jan; 63():32-48. PubMed ID: 27776972
[TBL] [Abstract][Full Text] [Related]
10. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
[TBL] [Abstract][Full Text] [Related]
11. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents.
Do MT; Kim HG; Choi JH; Jeong HG
Free Radic Biol Med; 2014 Sep; 74():21-34. PubMed ID: 24970682
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA Control of p53.
Liu J; Zhang C; Zhao Y; Feng Z
J Cell Biochem; 2017 Jan; 118(1):7-14. PubMed ID: 27216701
[TBL] [Abstract][Full Text] [Related]
13. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression.
Wang W; Cheng B; Miao L; Mei Y; Wu M
Cell Death Dis; 2013 Apr; 4(4):e574. PubMed ID: 23559009
[TBL] [Abstract][Full Text] [Related]
15. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
16. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p.
Towers CG; Guarnieri AL; Micalizzi DS; Harrell JC; Gillen AE; Kim J; Wang CA; Oliphant MUJ; Drasin DJ; Guney MA; Kabos P; Sartorius CA; Tan AC; Perou CM; Espinosa JM; Ford HL
Nat Commun; 2015 Dec; 6():10077. PubMed ID: 26687066
[TBL] [Abstract][Full Text] [Related]
17. Tumour suppression by p53: the importance of apoptosis and cellular senescence.
Zuckerman V; Wolyniec K; Sionov RV; Haupt S; Haupt Y
J Pathol; 2009 Sep; 219(1):3-15. PubMed ID: 19562738
[TBL] [Abstract][Full Text] [Related]
18. Targeting mutant p53 in cancer: a long road to precision therapy.
Mantovani F; Walerych D; Sal GD
FEBS J; 2017 Mar; 284(6):837-850. PubMed ID: 27808469
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.
Neilsen PM; Noll JE; Mattiske S; Bracken CP; Gregory PA; Schulz RB; Lim SP; Kumar R; Suetani RJ; Goodall GJ; Callen DF
Oncogene; 2013 Jun; 32(24):2992-3000. PubMed ID: 22797073
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 in cancer: new functions and therapeutic opportunities.
Muller PA; Vousden KH
Cancer Cell; 2014 Mar; 25(3):304-17. PubMed ID: 24651012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
